Date: 2015-01-23
Type of information: Resignation
Compound:
Company: Promethera Biosciences (Belgium)
Therapeutic area: Hepatic diseases - Liver diseases - Rare diseases - Regenerative medicine
Type agreement: resignation
Action mechanism:
Disease:
Details: * On January 23, 2015, Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, announces the resignation of Eric Halioua from his post as CEO of Promethera and all other functions within the company. He has decided to leave in order to concentrate on other projects.
As CEO of the company since it was founded in 2009, Eric Halioua was the driving force behind the operational and financial growth of Promethera Biosciences, working closely with Professor Etienne Sokal, the company’s scientific founder.
The search for his successor has already begun. The chairman of the board of directors, Dr. John Tchelingerian, will assume the role of acting CEO during the transition phase.
Financial terms:
Latest news:
